In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara® (ustekinumab) and Humira® (adalimumab), bringing the total ...

Alvotech is expanding its partnership with Advanz Pharma to commercialize new products in Europe, including a Kesimpta ...

The FDA launched an artificial intelligence tool Monday dubbed Elsa, with Commissioner Marty Makary hyping the effort’s early ...

Fresenius Kabi (“Fresenius”) announced that the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) had issued ...

Samsung Bioepis and Organon shared that the Food and Drug Administration has designated the Hadlima (adalimumab-bwwd) high- ...

New research confirms denosumab biosimilar SB16 matches Prolia in efficacy, offering a cost-effective treatment option for ...

The seasoned patent litigators join from Mayer Brown, bringing decades of high-stakes experience in pharma and biotech patent ...

Biosimilar associations advocate for lower development costs and streamlined regulations to enhance patient access to ...

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the ...

The FDA has approved Starjemza (ustekinumab-hmny), a biosimilar to Stelara (ustekinumab), for the treatment of various chronic inflammatory diseases.

The Food and Drug Administration has designated Hadlima (adalimumab-bwwd) an interchangeable biosimilar to Humira (adalimumab).

A live video webcast of the presentation will be available to the general public and can be accessed at ...